On a quiet February day, a small rare-disease company in Illinois won federal permission for a new liquid form of an old hormone medicine, one meant for people whose bodies no longer make enough vasopressin to hold water in balance. The change is modest in appearance but touches a long human struggle: families and clinicians have spent years shaping imperfect tablets into doses that must be exact, because too little brings thirst and too much can drown the body's chemistry in its own fluid. A ready-to-use solution offers a gentler path toward precision, though its real meaning will unfold quie
FDA Approves Eton's DESMODA, the First Oral Liquid Desmopressin for Central Diabetes Insipidus
Families have long relied on workarounds to get the dose right
Mark
Why does a liquid version of an old drug count as news?
Mimi
Because dosing in this condition is a balancing act. Too little desmopressin and the body loses water; too much and it retains it. Tablets come in fixed strengths, so families have been splitting or crushing them.
Mark
And the liquid fixes that?
Mimi
It lets the dose move in small steps, and it needs no refrigeration, mixing or shaking. The company says that supports precision for patients of all ages.
Luke
Worth noting who is saying this. The announcement is Eton's own, and the claims about precision come from the company and from two supportive voices it chose to quote. No outcome data is presented.
Mark
What about the market size?
Mimi
Eton estimates over 13,000 U.S. patients, roughly 3,000 to 4,000 of them children.
Luke
That's the company's estimate, as is the $30 to 50 million peak sales figure. Both are projections, not results.
Mark
Any risks to the patient?
Mimi
Hyponatremia is the big one. Fluid restriction matters, especially for children and older adults, and it's contraindicated with a history of low sodium.
Luke
And access runs through one specialty pharmacy, Anovo. Whether that smooths or narrows access, we don't know yet. Nothing is stated on price either.
Mimi
The $0 co-pay is for qualifying patients only, so the launch on March 9 will show how that works in practice.
El Pulso
- The FDA has cleared DESMODA, a ready-to-use oral liquid, for central diabetes insipidus in patients of all ages, a first for this formulation.
- Clinicians and families have long improvised with tablet splitting and crushing, and the new solution promises to end those workarounds.
- The launch on March 9 runs through a single specialty pharmacy, Anovo, which will handle prescriptions, insurance checks and co-pay help.
- The label's warning about hyponatremia sharpens the stakes, since excess fluid intake could cause water intoxication, seizures or worse.
- Eton projects $30 to $50 million in peak annual sales, and the coming months will show whether prescribers and patients embrace the liquid.
On a quiet February day, a small rare-disease company in Illinois won federal permission for a new liquid form of an old hormone medicine, one meant for people whose bodies no longer make enough vasopressin to hold water in balance. The change is modest in appearance but touches a long human struggle: families and clinicians have spent years shaping imperfect tablets into doses that must be exact, because too little brings thirst and too much can drown the body's chemistry in its own fluid. A ready-to-use solution offers a gentler path toward precision, though its real meaning will unfold quietly in homes and clinics over the months ahead.
On February 25, 2026, Eton Pharmaceuticals, a Nasdaq-listed rare disease company in Deer Park, Illinois, announced that the FDA had approved DESMODA, an oral desmopressin solution for central diabetes insipidus. The condition arises when the hypothalamus and posterior pituitary fail to produce enough vasopressin, and desmopressin is its standard treatment. Yet the dose must be tailored closely to each patient's daily water balance, and until now the available formulations were not built for fine adjustment.
Eton's chief executive, Sean Brynjelsen, described how clinicians and families often resorted to workarounds. DESMODA arrives as a ready-to-use liquid at 0.05 mg/mL, requiring no splitting, crushing, refrigeration, mixing or shaking. Outside experts, including Dr. Lewis Blevins of UCSF, welcomed the change as a way to support how therapy is started and managed, and Muriël Marks saw it as a step toward getting the dose right every time.
The drug will be available March 9 exclusively through Anovo, which will run the Eton Cares Program to help with prescriptions, insurance and co-pay assistance. The label, however, carries serious cautions. Hyponatremia is the central danger, since excess fluid combined with the drug can lead to water intoxication, seizures or death, so fluid restriction is recommended, especially for children and older adults. What comes next is the launch itself and whether sales reach the company's estimate.
On February 25, 2026, Eton Pharmaceuticals, a Nasdaq-listed rare disease company based in Deer Park, Illinois, announced that the U.S. Food and Drug Administration had approved its New Drug Application for DESMODA, a desmopressin acetate oral solution. The drug is indicated for central diabetes insipidus, also called arginine vasopressin deficiency (AVP-D), as antidiuretic replacement therapy for patients of all ages. Eton describes it as the first and only FDA-approved oral liquid form of desmopressin.
Central diabetes insipidus is rare but serious. It arises when the hypothalamus and posterior pituitary do not produce enough of the hormone vasopressin. Desmopressin is the standard treatment, but the dose has to be tailored to each patient to avoid problems from too much or too little. According to the company, effective long-term management depends on matching the dose to a patient's daily pattern of water balance.
That is where the formulation matters. Eton's chief executive, Sean Brynjelsen, said clinicians have mostly relied on formulations not designed for fine dose adjustments, or ones with other administration problems, so clinicians and families often resorted to workarounds. DESMODA is a ready-to-use solution at 0.05 mg/mL. It requires no tablet splitting, crushing, refrigeration, mixing, or shaking. A liquid, the company says, lets clinicians adjust therapy in small increments and change the dose over time as needs evolve.
Two outside voices were quoted in the announcement. Dr. Lewis Blevins, director of the California Center for Pituitary Disorders and a professor of medicine and neurological surgery at the University of California, San Francisco, said a liquid desmopressin could meaningfully support how therapy is started and managed, and that it addresses real-world challenges for clinicians and families. Muriël Marks, a board member of Worldwide Adrenal and Pituitary Organizations, called it a meaningful improvement because it helps ensure the dose is right every time, which matters where a wrong dose can have a large impact.
Eton estimates more than 13,000 people in the U.S. have central diabetes insipidus, including roughly 3,000 to 4,000 children. It projects peak annual sales of $30 million to $50 million and says patent protection extends through 2044. Brynjelsen called the launch one of the most important in the company's history, building on its pediatric endocrinology platform. The same sales team already promotes ALKINDI SPRINKLE and KHINDIVI (both hydrocortisone) and INCRELEX (mecasermin).
DESMODA is expected to be available March 9, exclusively through Anovo, a specialty pharmacy serving rare and chronic conditions. Anovo will run the Eton Cares Program with Eton, covering prescription fulfillment, insurance benefits investigation, educational support and financial assistance for qualified patients. Co-pay assistance is intended to bring the co-pay to $0 for eligible patients. Prescribers can e-prescribe by selecting Anovo #5 or fax a referral form to 855-813-2039.
The label carries significant cautions. DESMODA is not for nephrogenic diabetes insipidus. It is contraindicated in patients with hypersensitivity to desmopressin or its components, moderate to severe renal impairment (adult creatinine clearance below 50 mL/min), or current or past hyponatremia. The main warning is hyponatremia: excess fluid intake while desmopressin limits urine output can cause water intoxication, with severe cases leading to seizures, coma, respiratory arrest or death. Fluid restriction is recommended, especially in children and older adults. The label also flags fluid retention, rare hypersensitivity reactions, and caution in low-birth-weight and preterm neonates because the product contains benzoic acid.
What to watch next is the March 9 launch, how prescribing takes shape through the single Anovo channel, and whether sales approach the company's own $30 million to $50 million estimate.
Citas Notables
A liquid option like DESMODA is a meaningful improvement because it helps make sure the dose is always right, every time.— Muriël Marks, board member, Worldwide Adrenal and Pituitary Organizations
DESMODA represents one of the most important product launches in Eton's history.— Sean Brynjelsen, CEO, Eton Pharmaceuticals
Quieres la nota completa?
Lee el original en The Manila Times ↗
Health & Medicine